Aurinia Pharmaceuticals Inc. (AUPH) NASDAQ
15.61
+0.14(+0.90%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
15.61
+0.14(+0.90%)
Currency In USD
Address
4464 Markham Street
Edmonton, BC V8Z 7X8
Canada
Phone
12507084272
Sector
Healthcare
Industry
Biotechnology
Employees
130
First IPO Date
September 03, 2014
| Name | Title | Pay | Year Born |
| Peter S. Greenleaf | President, Chief Executive Officer & Director | 1.59M | 1970 |
| Gregory F. Keenan | Chief Medical Officer | 779,114 | 1961 |
| Stephen Robertson | Executive Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer | 799,518 | 1982 |
| Joseph Miller | Chief Financial Officer | 866,870 | 1974 |
| Matthew Maxwell Donley | Chief Operations Officer | 933,951 | 1969 |
| Premchandran Ramiya | Senior Vice President of Manufacturing & Supply Chain | 0 | 1961 |
| Andrea Levin Christopher | Executive Director of Corporate Communications & Investor Relations | 0 | N/A |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.